Intravenous Vitamin C for Cancer Therapy - Identifying the Current Gaps in Our Knowledge.
Intravenous Vitamin C for Cancer Therapy - Identifying the Current Gaps in Our Knowledge.
复制标题
DOI：
10.3389/fphys.2018.01182
复制
发表时间：
2018
影响因子：
4
通讯作者：
Cook J
中科院分区：
文献类型：
--
作者：
Carr AC;Cook J
静脉注射维生素C（IVC）用于癌症治疗长期以来一直是一个激烈争议的领域。尽管如此，高剂量IVC已经由补充医疗保健从业者和医生管理了几十年，几乎没有证据基础，导致临床实践不一致。在这篇综述中，我们提出了一系列与研究人员和临床医生以及患者本身相关的问题，以确定我们目前的知识差距。这些问题包括：肿瘤患者的维生素C状态是否受损？静脉注射是维生素C给药的最佳途径吗？IVC安全吗？IVC是否会干扰化疗或放疗？IVC是否能减少化疗的毒副作用，提高生活质量？IVC的相关作用机制是什么？IVC治疗的最佳剂量、频率和持续时间是多少？在过去的20年里，研究人员取得了巨大的进步，并解决了许多重要的方面，如最佳给药途径、安全性、与化疗的相互作用、生活质量和潜在的作用机制。然而，我们仍然不知道围绕最佳临床实践的一些基本问题的答案，例如对肿瘤患者进行IVC的量、频率和持续时间。这些问题为基础研究和未来的临床试验指明了方向。
The use of intravenous vitamin C (IVC) for cancer therapy has long been an area of intense controversy. Despite this, high dose IVC has been administered for decades by complementary health care practitioners and physicians, with little evidence base resulting in inconsistent clinical practice. In this review we pose a series of questions of relevance to both researchers and clinicians, and also patients themselves, in order to identify current gaps in our knowledge. These questions include: Do oncology patients have compromised vitamin C status? Is intravenous the optimal route of vitamin C administration? Is IVC safe? Does IVC interfere with chemotherapy or radiotherapy? Does IVC decrease the toxic side effects of chemotherapy and improve quality of life? What are the relevant mechanisms of action of IVC? What are the optimal doses, frequency, and duration of IVC therapy? Researchers have made massive strides over the last 20 years and have addressed many of these important aspects, such as the best route for administration, safety, interactions with chemotherapy, quality of life, and potential mechanisms of action. However, we still do not know the answers to a number of fundamental questions around best clinical practice, such as how much, how often and for how long to administer IVC to oncology patients. These questions point the way forward for both basic research and future clinical trials.
登录
查看更多内容
影响因子：
4
作者：
Campbell, Elizabeth J.;Vissers, Margreet C. M.;Bozonet, Stephanie;Dyer, Arron;Robinson, Bridget A.;Dachs, Gabi U.
通讯作者：
Dachs, Gabi U.
DOI：
10.1080/01635581.2014.948211
发表时间：
2014-10-03
影响因子：
2.9
作者：
Chen, Ming-Feng;Yang, Chih-Min;Hu, Miao-Lin
通讯作者：
Hu, Miao-Lin
维生素C在健康和疾病中的表观遗传作用。
DOI：
10.1007/s00018-016-2145-x
发表时间：
2016-04
期刊：
Cellular and molecular life sciences : CMLS
影响因子：
--
作者：
Camarena V;Wang G
通讯作者：
Wang G
影响因子：
64.8
作者：
Agathocleous M;Meacham CE;Burgess RJ;Piskounova E;Zhao Z;Crane GM;Cowin BL;Bruner E;Murphy MM;Chen W;Spangrude GJ;Hu Z;DeBerardinis RJ;Morrison SJ
通讯作者：
Morrison SJ
影响因子：
5.9
作者：
Carr AC;Maggini S
通讯作者：
Maggini S